Trial of Romidepsin and Bortezomib for Multiple Myeloma
Status:
Terminated
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a phase II, open-label, multicenter, dual-strata study designed to evaluate the
efficacy and safety of IV romidepsin given in combination with IV bortezomib for multiple
myeloma (MM) patients with refractory or relapsed disease. Patients will be enrolled into one
of two strata, bortezomib-resistant or bortezomib non-resistant.